FAS and central nervous system cancer: Additionally, activating CD95 by ligand binding enhanced cell invasion through a PI3K/glycogen synthase kinase 3-beta pathway/matrix metalloproteinase-mediated pathway in glioblastoma cells, and blockade of CD95-activated signaling suppressed glioma invasion in an in vivo mouse model [15].